Morgan Stanley Bets on These 3 Stocks; Sees Over 40% Upside
Concerns Mount – FDA May Approve Deadly Vaccine
Bill Gates embroiled in controversy over coronavirus vaccine safety
NIH Raises Concerns About Potential Safety Issues Associated with AstraZeneca Vaccine
Former FDA Executive on COVID-19 and Convalescent Plasma
News briefing: Top FDA official exits; Sun Genomics closes $9.25M Series A
Abbott Starts Shipping 15-Minute Covid-19 Test After FDA Emergency Use Nod
Why AstraZeneca and others racing to make a COVID-19 vaccine should be more open about the process
Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy
Covid-19 Vaccine Makers’ Pledge May Not Quell Uprising
Penumbra Inc.’s Catheter Fail: Broken Tips and Lost Lives
NIH ‘very concerned’ about serious side effect in AstraZeneca's PhIII Covid-19 trial
Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
Bill Gates Slams FDA, Doubts Agency Can Be Trusted With COVID-19 Vaccine
AstraZeneca’s Pivotal Covid-19 Vaccine Trial Kept On Hold In US- Report
Marinus Spikes 63% On Positive Phase 3 Trial For Rare Genetic Epilepsy
US Close – All about M&A today, Stopgap likely, OPEC+ to stay the course, Gold shines, Biden Momentum
Cool eyes on fever screening: Optimizing infrared thermography
Moderna or BioNTech: J.P. Morgan Lays Odds On the Race to a COVID-19 Vaccine
Monday’s Market Snapshot: Here’s What You Need To Know Right Now
Dynavax Scores Supply Deal For Valneva’s Covid-19 Vaccine; Street Bullish
These 3 Penny Stocks Could Double (Or More), Says BTIG
Futures Surge On Monday Merger Mania, Fresh Vaccine Hopes
Big pharma's safety pledge isn't enough to build public confidence in COVID-19 vaccine – here's what will
Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens
Regeneron, Sanofi’s Dupixent Nabs Breakthrough Tag For Esophagus Disease
Gilead Inks $21B Immunomedics Deal, Adding Trodelvy To Its Oncology Arsenal
Pfizer CEO: Our Covid-19 Vaccine Could Be Ready For Americans By Year-End
Pfizer, BioNTech Propose Expansion Of Phase 3 Covid-19 Vaccine Trial
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports